





The Intersection of HIV and Substance Use: Enhancing the Care Continuum with Evidence-Based Practices

Training Series: Session 3
January 22, 2025


Copyright © 2024 Health Management Associates, Inc. All rights reserved. The content of this presentation is PROPRIETARY and CONFIDENTIAL. It is the property of Health Management Associates, Inc. and may be the subject of other intellectual property. No part may be reproduced without written permission from Health Management Associates, Inc.


1


UTILIZING ZOOM


- » Ensure your audio is linked to your Zoom participant ID.
 - » If you joined the audio by computer microphone and speaker, then you're all set.
 - » If you joined the audio with a phone and did not enter your unique participant ID then enter #<your participant ID># on your phone now.

Note: Your unique participant ID can be found by clicking on the lower left corner of your Zoom screen where it says, 'Join Audio' and your Participant ID will appear.
- » Ensure you are on MUTE and your camera is ON. On the bottom left corner of your screen, you will see a red line through the microphone


ON MUTE


Microphone ON



Camera OFF


Camera ON
- » Your participation throughout today via chat is appreciated!
 - » Locate the chat box. On the bottom middle of your screen, click on the chat icon. This will open the "Zoom Group Chat" pane on the right side of your screen. You will see messages throughout the webinar on there. When prompted by the presenters, type in your answers or questions there.

© 2024 Health Management Associates, Inc. All Rights Reserved.




HEALTH MANAGEMENT ASSOCIATES


2



2

UTILIZING ZOOM

- » If you would like to enable closed captions during this session, please follow the steps below.
 - » On the Zoom room toolbar, tap the **Captions**  icon.
 - » You may need to tap the **More**  icon first to see the option.
 - » Ensure that the **Show Captions** toggle  is enabled.
- » If you have any issues or questions about this feature, message Gabriel Velazquez in the chat and he can assist you.



© 2024 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

3

3

HOUSEKEEPING

Today is Session 3

Please complete the evaluation for the webinar that will be sent out via email after each session.

You will be receiving a PDF of today's presentation.

This session is being recorded.

Follow-up questions?

Contact Gabriel Velazquez:
gvelazquez@healthmanagement.com

© 2024 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

4

4

CEUS AND CMES ELIGIBILITY AND DISTRIBUTION

- » This series is eligible for both CEUs
- » These activities have been approved for CEUs by the Minnesota Board of Behavioral Health and Therapy for 3 hours of credit for LADCs and LPC/LPCCs (total of 12 hours if all four sessions are fully attended)
- » To qualify for CEUs, you are required to
 1. Complete the pre-training quiz
 2. Be in attendance for the entire session
 3. Complete the accompanying evaluation survey for each session attended
 4. Complete the post-training quiz
- » CEU certificates will be issued approximately 1-2 weeks AFTER the completion of the series (Session 4: January 29th).


Follow-up questions?
 Contact Gabriel Velazquez:
 gvelazquez@healthmanagement.com

© 2025 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
5


5

ACKNOWLEDGMENTS


We would also like to thank our community partners for their support in developing this curriculum.




HIV REDUCTION STRATEGIES




the **Aliveness** project



Indigenous Peoples Task Force



RAN
RURAL AIDS ACTION NETWORK
Providing Care, Service, and Support




SOUTH DAKOTA COLLEGE OF HEALTH CARE

© 2025 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
6

6

LAND ACKNOWLEDGMENT



Every community owes its existence and vitality to generations from around the world who have contributed their hopes, dreams, and energy to making the history that led to this moment. Some were brought here against their will, some were drawn to leave their distant homes in hope of a better life, and some have lived on this land for more generations than can be counted. Truth and acknowledgment are critical to building mutual respect and connection across all barriers of heritage and difference.

We begin this effort to acknowledge what is buried by honoring the truth. **We are standing on the ancestral lands of the Dakota people. We want to acknowledge the Dakota, the Ojibwe (pronounced ow-jeeb-way), the Ho Chunk, and the other nations of people who also call this place home.** We pay respects to their elders past and present.


Please take a moment to consider the treaties made by the Tribal nations that entitle non-Native people to live and work on traditional Native lands. Consider the many legacies of violence, displacement, migration, and settlement that bring us together here today. Please join us in uncovering such truths at any and all public events.*

*This is the acknowledgment given in the USDAC Honor Native Land Guide – edited to reflect this space by Shannon Geshick, MTAG, Executive Director Minnesota Indian Affairs Council

© 2025 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
7


7

TODAY'S PRESENTERS



Charles Robbins, MBA
(he/him/his)

Principal
Health Management Associates



Shannon Robinson, MD
(she/her/hers)

Principal
Health Management Associates

© 2025 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
8

8

DISCLOSURES

Faculty	Nature of Commercial Interest
Charles Robbins, MBA	Mr. Robbins discloses that he is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of health care clients.
Shannon Robinson, MD	Dr. Robinson discloses that she is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of health care clients and that her husband manufactures suicide resistant bedding and garments.
Jeanene Smith, MD	Dr. Smith discloses that she is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of health care clients.

© 2025 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 9

9

AGENDA FOR WEBINAR SERIES

Session	Topics
#1 WEDNESDAY, JANUARY 8 12:00 pm to 3:00 pm	<input type="checkbox"/> Screening, and Assessment <input type="checkbox"/> Understanding HIV <input type="checkbox"/> HIV Testing, Treatment and Prevention <input type="checkbox"/> The Science of Addiction
#2 WEDNESDAY, JANUARY 22 12:00 pm to 3:00 pm	<input type="checkbox"/> Ethical and Legal Issues <input type="checkbox"/> Funding and Policy Considerations <input type="checkbox"/> HIV Risk Reduction <input type="checkbox"/> SUD Harm Reduction <input type="checkbox"/> HIV and Stigma <input type="checkbox"/> Motivational Interviewing
#3 WEDNESDAY, JANUARY 22 12:00 pm to 3:00 pm	<input type="checkbox"/> Working with Justice Involved Persons <input type="checkbox"/> Substance Use Disorder Treatment with Medications <input type="checkbox"/> Mental Health Treatment and Counseling <input type="checkbox"/> Stimulant Use <input type="checkbox"/> Chem Sex
#4 WEDNESDAY, JANUARY 29 12:00 pm to 3:00 pm	<input type="checkbox"/> Cultural, Racial and Sexual Identities <input type="checkbox"/> Pregnancy and HIV, SUD/ODU <input type="checkbox"/> Accessing, Obtaining, and Integrating Services for Individuals with HIV and SUD in Minnesota

© 2025 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 10

10

TIME FOR A POLL

Please indicate the sector(s) in which you currently serve:

- A. Community based organizations (Social Services, HIV, LGBT, etc.)
- B. Corrections (includes Probation, Jail, Prison)
- C. County Behavioral Health, Public Health, Human Services
- D. Non-county behavioral health
- E. Federally Qualified Health Center (FQHC)
- F. Narcotic Treatment Program/Opioid Treatment Program
- G. Outpatient Treatment Program
- H. Residential Treatment Program
- I. Aftercare services (e.g., sober living, other recovery housing, recovery community centers, etc.)
- J. Harm Reduction Services/SSPs
- K. Other (please specify in the chat)

© 2025 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 11

11

TIME FOR A POLL

Please indicate your primary role or discipline:

- A. Physicians, Physician Assistant, Nurse Practitioners, Nurses (RN, LVN)
- B. Social Workers, Psychologists, LMFTs
- C. Addiction Counselors (LADCs)
- D. Peer Recovery Support Positions
- E. Substance Use Navigators (SUNs)
- F. Administrators, Program Managers
- G. Case/ Care Manager
- H. Criminal Justice Professionals
- I. Community Members
- J. Other (please specify in the chat)

© 2025 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 12

12

WORKING WITH JUSTICE-INVOLVED INDIVIDUALS

13

LEARNING OBJECTIVES:

I

Describe the importance of substance use disorder treatment with medications in criminal justice settings

II


List 3 actions to take to ensure continuity of care for clients upon release from justice settings

III


Compare and contrast FDA approved medications for Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD), and opioid reversal

HEALTH MANAGEMENT ASSOCIATES 14


14




15



16



17



18

MINNESOTA DEPARTMENT OF CORRECTIONS ADULT PRISON POPULATION SUMMARY (AS OF 01/01/2024)

Top Six Offenses	Count	Percentage (%)
Homicide	1,636	19.8%
Criminal Sexual Conduct	1,599	19.3%
Drugs	1,323	16.0%
Weapons	822	9.9%
Assault	705	8.5%
DWI	393	4.7%


Note: Percentages are based on the total population of 8,274

Releases (FY2023)	Count	Percentage (%)
Supervised Release/Parole	3,779	78.9%
Community Programs	689	14.4%
Discharge	381	5.8%
Other	42	0.9%
Total	4,791	100.0%


Source: [Minnesota Department of Corrections Adult Inmate Profile as of 01/01/2024 \(mni.gov\)](https://www.mn.gov/bsc/assets/Adult%20Prison%20Population%20Summary%207-1-2023_tcm1089-589994.pdf)

HEALTH MANAGEMENT ASSOCIATES

19



20



BURDEN OF SUBSTANCE USE DISORDER (SUD) IN CARCERAL SETTINGS

- » 63% of people in jail and 58% in prison have a SUD.*
- » Historically jails withdrew people from medication for addiction treatment.**
- » Outcomes are much better if people are continued on treatment.**
- » 77% of deaths within 2 weeks of release are related to overdose.
- » This can be decreased by 60-80% with access to medication ***

GUIDELINES FOR MANAGING SUBSTANCE WITHDRAWAL IN JAILS

A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals

June 2023

Source: <https://www.samhsa.gov/criminal-justice-book>
 **Rich 2016; **Korick 2009.
 ***Green 2019; Lem 2023

HEALTH MANAGEMENT ASSOCIATES

- ### SERVICES PROVIDED IN CARCERAL SETTINGS
- » Screening for medical, mental health, substance use disorders and dental issues
 - » Assessments for medical, mental health, substance use disorders and dental issues
 - » Acute and chronic treatment of these conditions, including
 - » Overdose reversal & overdose prevention education
 - » Withdrawal management
 - » Medications
 - » Counseling
 - » Preventative care
 - » Linkage to care in the community
 - » Naloxone upon release
- HEALTH MANAGEMENT ASSOCIATES

TRANSITION OF CARE

- » Transition of Care – The movement of a patient from one setting of care (hospital, ambulatory primary care practice, ambulatory specialty care practice, long-term care, home health, rehabilitation facility) to another.
- » Important Issues Regarding Release
 - » Narcan® on release
 - » Warm handoff to community provider
 - » Challenges in jails and beyond
 - » No clear discharge date/time
 - » Release not correlated to clinical condition
 - » Housing options frequently suboptimal in supporting recovery
 - » Variability in provision of substance use disorder treatment with medications

Photo Source - Ashley Justice on Unsplash

Source: <https://store.samhsa.gov/sites/default/files/07/prv/sma16-4998.pdf>

HEALTH MANAGEMENT ASSOCIATES

COMMUNITY OPPORTUNITIES TO MINIMIZE INCARCERATION

- » Early identification of individuals with mental and substance use disorders at all points of contact with the justice system – pre-arrest, booking, adjudication, reentry.
- » Use of validated screening and assessment tools to establish who needs treatment.
- » Diversion of individuals from the justice system into community-based treatment.
- » Engaging law enforcement, first responders, and crisis management teams, justice court personnel, and community treatment providers in diversion strategies that meet both clinical and public safety needs.

Source: <https://store.samhsa.gov/sites/default/files/d7/priv/sma16-4998.pdf>

© 2016 Health Management Associates Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

25

25

COMMUNITY OPPORTUNITIES TO MINIMIZE INCARCERATION CONT.

- » Provision of training and technical assistance for law enforcement officers, juvenile and family court judges, probation officers, and other judicial decision-makers on behavioral health issues; and conversely, training for behavioral health treatment providers on criminogenic risk and the criminal and juvenile justice system.
- » Provision of an array of services and supports to enable successful reentry into the community for those transitioning from incarceration or detention including housing.
- » Assurance of equitable opportunities for diversion and linkage to community services and supports for all populations in order to decrease disproportionate minority contact with the justice system.
- » Promotion of cross-sector collaboration to better serve these populations dually involved with the behavioral health and criminal justice systems.

Source: <https://store.samhsa.gov/sites/default/files/d7/priv/sma16-4998.pdf>

© 2016 Health Management Associates Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

26

26

TIME FOR A POLL

Statement: My organization has an active working process to identify and provide a soft landing into the community for patients with complex care management needs related to addiction and HIV upon release from carceral settings.

- A. Yes
- B. No
- C. Not Sure

© 2016 Health Management Associates Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

27

27

SUBSTANCE USE DISORDER TREATMENT WITH MEDICATIONS

28

WHAT IS SUBSTANCE USE DISORDER TREATMENT WITH MEDICATIONS?

- » The use of FDA-approved prescription medications, usually in combination with counseling and behavioral therapies, to provide a whole-person approach to the treatment of substance use disorders (SUD).
- » When discussing medication for opioid use disorder this is frequently referred to as Medications for Opioid Use Disorder (MOUD).
- » MOUD has proven clinically effective to alleviate symptoms of withdrawal & reduce cravings. MOUD maintenance has been proven to cut overdose rates in half and decrease rates of HIV and hepatitis C transmission.
- » Research shows that a combination of MOUD and behavioral therapies is a successful method to treat OUD.

© 2023 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
29

29

WHICH SUBSTANCE USE DISORDERS ARE TREATED WITH MEDICATIONS?

Substance Use Disorder's with FDA Approved Medications	No FDA Approved Medications

© 2023 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
30

30

WHY IS MOUD IMPORTANT?

Treat Withdrawal	Address Dopamine Depletion	Treat OUD/Achieve Results
<ul style="list-style-type: none"> Muscle pain, dilated pupils, nausea, diarrhea, abdominal cramping, piloerection Lasts 14 days Methadone or buprenorphine are recommended over abrupt cessation due to risk of return to use, overdose (OD) & death 	<ul style="list-style-type: none"> Reward/motivation pathway abnormalities persists for months after people stop using Treated with methadone or buprenorphine 	<ul style="list-style-type: none"> Abstinence based treatment results in 85% using opioids within 1 year MOUD decreases <ul style="list-style-type: none"> Use Craving Complications from IVDU Criminal behavior MOUD increases retention in treatment

Sources: ASAM, (2020) National Practice Guidelines for the Treatment of OUD, Mattick, RP & Hall W (1996) Lancet 347: 8994, 97-100; Mattick, RP et al. (2008) Cochrane Systematic Review; Mattick, RP, et al. (2009) Cochrane Systematic Review; Lohmeier, P et al. (2008) Cochrane Systematic Review; Krupitsky et al. (2011) Lancet 377, 1506-13; Kalko et al. (2003) Lancet 361(9358):852-8; Rich, JD, et al. (2015) Lancet

© 2023 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
31


31

FDA APPROVED MEDICATION FOR OUD


<div style="background-color: #0056b3; color: white; padding: 5px; margin-bottom: 5px;">Agonist Treatment (turns on the receptor):</div> <ul style="list-style-type: none"> Methadone- approved for cough in 1940s, for OUD 1972 Buprenorphine (Suboxone™, Subutex™, Sublocade™ and Brixadi™)- approved in 1981 for pain; oral approved for OUD 2002, patch, implants & injection later 	<div style="background-color: #0056b3; color: white; padding: 5px; margin-bottom: 5px;">Antagonist Treatment (blocks receptor from turning on):</div> <ul style="list-style-type: none"> Naltrexone (Revia™)- oral approved 1984; injectable (Vivitrol™) 2006 for AUD, 2010 for OUD Naloxone- approved 1971, autoinjector 2014, nasal spray (Narcan™) 2015 Nalmefene (Opvee™) - injectable approved 1995; nasal spray approved 2023
---	--

© 2023 Health Management Associates, Inc. All Rights Reserved.
HEALTH MANAGEMENT ASSOCIATES
32

32



33



34

METHADONE: WHAT AND FOR WHOM?

- » Mu opioid receptor full agonist
 - » No "ceiling effect"
- » Can start prior to being in withdrawal
- » Reaching a therapeutic dose takes time
 - » <60 mg/d is not therapeutic
 - » Typical dose 60-120 mg/d
 - » Increased frequency and daily dose required during pregnancy
- » Several drug-drug interactions
- » Illegal to write prescription for methadone to treat OUD unless:
 - » Narcotic Treatment Program (NTP)
 - » Covering a gap of no more than 3 days
 - » Patient is in a DEA licensed clinic or hospital with another condition

Patients with a more severe OUD, such as injecting opioids

Patients who have not reached treatment goals with other MOUD

Patients who would benefit from the closest follow up

HEALTH MANAGEMENT ASSOCIATES

35

METHADONE: GENERAL FEDERAL REGULATIONS

Delivered via observed dosing	Once patient is stable, can be given take-home doses (varies by state)
Highly monitored in a Narcotics or Opioid Treatment Program setting (NTP/OTP)	Many requirements for treating patients: therapy, toxicology...

<https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder>


HEALTH MANAGEMENT ASSOCIATES

36

METHADONE: EFFICACY DATA

- » Methadone resulted in 33% fewer opioid positive toxicology tests compared to those receiving no medication* when everyone receives psychosocial treatment
- » 4.4x more likely to stay in treatment *
- » Reduced crime *
- » Reduced infectious disease*
- » Reduced death**

Source:
 * Matick 2009 Cochrane Review
 ** Wakeman 2020 JAMA Open Network



HEALTH MANAGEMENT ASSOCIATES

37

BUPRENORPHINE: WHAT AND FOR WHOM?

- » Partial mu opioid agonist with ceiling effect
 - » Doses >32 mg don't cause greater respiratory effects
 - » Available sublingually alone or in combination w/naloxone and as a long acting- weekly or monthly injections
 - » Different formulations (sub-lingual [SL] or buccal pill/film, long-acting injectable)
- » Greater binding affinity than full agonists
 - » Start buprenorphine when client in moderate withdrawal (to avoid causing precipitated withdrawal)
 - » Other opioids are not as effective when buprenorphine is present
 - » Typical dose is 16-32 mg/d
 - » Increased frequency and daily dose required during pregnancy
- » Fewer drug-drug interactions than methadone
https://downloads.asam.org/stefinity-production-blobs/docs/default-source/advocacy/letters-and-comments/asam_clinical_considerations_buprenorphine.212-11.pdf

Opioid use disorder or withdrawal


Patient wants agonist treatment

HEALTH MANAGEMENT ASSOCIATES

38

BUPRENORPHINE EFFICACY

- » Rate of return to opioid use for persons taking placebo was 100% vs 25% for persons taking buprenorphine
- » If taking ≥ 16 mg buprenorphine you are 1.82 times more likely to stay in treatment than if on placebo
- » Decreased crime, infectious disease and death*



Source:
 NIDA Medications to Treat Opioid Use Disorder Research Report Updated December 2021
 Matick 2014 Cochrane Review
 * Wakeman 2020 JAMA Open Network

HEALTH MANAGEMENT ASSOCIATES

39

INTERVENTIONS TO REDUCE HARMS RELATED TO DRUG USE AMONG PEOPLE WHO EXPERIENCE INCARCERATION

- » 126 studies reviewed of 18 different interventions
 - » Receiving opioid agonist treatment in prison reduces risk of death in prison
 - » Receiving opioid agonist treatment in first 4 weeks following release reduces risk of death in community
 - » More likely to engage in treatment and take agonist treatment if it was prescribed while in prison
 - » Therapeutic communities in prison reduce rearrest

Macdonald C, Macpherson G, Leppan O, Tran LT, Cunningham EB, Hajarizadeh B, Grebely J, Farrell M, Altice FL, Degenhardt L. Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis. *Lancet Public Health*. 2024 Sep;9(9):e684-e699. doi: 10.1016/S2468-2667(24)00160-9. PMID: 39214637.

HEALTH MANAGEMENT ASSOCIATES

40

NALTREXONE: WHAT AND FOR WHOM?

- » Mu opioid antagonist with high, competitive binding affinity
- » Does not treat withdrawal or low dopamine levels
- » Must be opioid free x 14 days before starting and/or have completed withdrawal if recently using
- » No evidence of decreased mortality

Patients with a high degree of motivation (dopamine)

Patients with a history of OUD and Alcohol Use Disorder (AUD): FDA approved for both

Patients who did not reach treatment goals with methadone or buprenorphine


Can be useful for occasional use or after discontinuation of methadone or buprenorphine

Source: Laroche, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. *Annals of Internal Medicine*. 1993 (2018) 137-45. Wakeman, SE, et al. (2020) Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. *JAMA Open Network*, 3 (2). © 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES 41


41


NALTREXONE: GENERAL REGULATIONS



No Federal regulations inhibit the use

Not all BH clinics have RN to give injections






Multiple formulations:
 -Pills at 25mg and 50 mg (50-100 mg for AUD)
 -Long acting injectable 380mg (28-30 days) for AUD and OUD

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 42

42

NALTREXONE: EFFICACY DATA

- » Extended Release (XR) Naltrexone 90% opioid abstinence toxicology tests vs. 35% placebo*
 - » Decreased incarceration**
- » XR Naltrexone vs usual care in HIV clinic***
 - » Fewer days of opioid use for those on XR Naltrexone



This Photo by Unknown Author is licensed under CC BY

Source: Krupitsky 2011 Lancet
 **Minozzi 2011 Cochrane Review
 *** Korhola 2022

HEALTH MANAGEMENT ASSOCIATES 43

43

NALOXONE: OD REVERSAL AGENT AS HARM REDUCTION

- » Mu opioid antagonist
- » Shorter half-life & more rapid onset of action than naltrexone
- » High affinity, competitive binding & displaces agonists
- » Intranasal or intramuscular by bystander
- » May require more than one dose
- » Opioids have longer half-life than naloxone
- » Saves lives; no evidence for increasing drug use
- » Good Samaritan law in MN
- » Available over the counter

In 2019, 77.3% of 33,084 opioid-involved overdose deaths across 37 states + the District of Columbia had no evidence of naloxone administration.

Source: Quinn, et al. (2022) Naloxone administration among opioid-involved overdose deaths in 38 United States jurisdictions in the State Level Opioid Drug Overdose Reporting System, 2019. *Drug and alcohol dependence*, 235, 109467.

HEALTH MANAGEMENT ASSOCIATES 44

44

NALOXONE DISTRIBUTORS IN MINNESOTA

- » In response to the opioid crisis in Minnesota, the Minnesota Department of Health (MDH) developed **KnowTheDangers.com** to provide clear, fact-based information, access to recovery programs, and essential harm reduction resources.
- » One key resource on the site is the Naloxone Finder, which helps locate naloxone distribution sites.



© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

45

45

NALOXONE RESOURCES

- » <https://www.health.state.mn.us/communities/opioids/opioid-dashboard/resources.html#naloxone>
- » University of Minnesota Naloxone Resources <https://www.pharmacy.umn.edu/degrees-and-programs/continuing-pharmacy-education/continuing-education-courses/naloxone>
- » Naloxone overdose training and kits free of charge. The following community-based organizations provide Naloxone overdose training and kits free of charge:
- » [Steve Rummeler HOPE Network](#)—Call 952-943-3937 or sign up for training from the [Steve Rummeler HOPE Network](#).
- » [Rural AIDS Action Network \(RAAN\)](#)—Call 320-257-3036.
- » [Red Door Clinic](#)—Call 612-543-5555.
- » [Indigenous Peoples Task Force](#)—Call 612-870-1723.
- » [Lutheran Social Services](#)—Call 800-582-5260.
- » <https://knowthedangers.com/>

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

46

46

TIME FOR A POLL

Do you know if your organization is currently prescribing (or providing) or doing any training on naloxone?

- A. Yes
- B. No
- C. I Don't Know

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

47

47

HOW LONG TO TREAT OUD?

- » Studies of all FDA approved meds for OUD indicate a risk of return to opioid use upon discontinuation of meds
- » **Year(s) post sobriety**, if making appropriate changes to decrease likelihood of future substance use, stable in recovery and life and wants to discontinue
 - » Social Support that supports recovery
 - » Active in 12 step meetings or
 - » Active in Self-Management and Recovery Training (SMART) meetings or
 - » Active in church
 - » Not living with people who are using
 - » Able to handle interpersonal conflicts without returning to use
 - » Avoid tapering during big life transitions such as leaving incarceration, pregnancy or delivery, moving across the country, changing jobs

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

48

48

TO TAPER OR NOT TO TAPER?

Evidence is clear that long-term or indefinite treatment with medications for OUDs is often required for effective and sustained outcomes¹

In practice, successful tapers from methadone or buprenorphine typically occur in only about 15 percent of cases^{2,3}

According to the U.S. Surgeon General, successful tapers typically occur, if at all, when individuals have been treated with Medicated Assisted Treatment (MAT) for at least 3 years⁴

1. National Academy of Sciences, Engineering, and Medicine. (2019). *Medications for opioid use disorder save lives*. Washington, DC: The National Academies Press.
2. Steels, R., Sun, H., Evans, P., Mackie, D. C., Aday, M. D., Han, Y. L. et al. (2012). Defining opioid patient characteristics of successful tapers following methadone maintenance treatment: Results from a population-based retrospective cohort study. *Addiction*, 107, 1421-1429.
3. Substance Abuse and Mental Health Services Administration. (2018). *Medications for opioid use disorder: Treatment improvement protocol (TIP 63) for healthcare and addiction professionals, policy makers, patients and families*. (Rep. No. HHS Publication No. SMA 18-5063). Bethesda, MD: Author.
4. Substance Abuse and Mental Health Services Administration and Office of the Surgeon General. (2018). *Facing addiction in America: The Surgeon General's spotlight on opioids*. Washington, DC: US Department of Health and Human Services.

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

49

49

REFERENCES: OUD MEDICATION

- "Census of Jails (COJ)." Bureau of Justice Statistics, bjs.ojp.gov/data-collection/census-jails-coj. Accessed 17 Jan. 2024.
- Green, T. C. et al. (2018). Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. *JAMA psychiatry*, 75(4), 405-407. <https://doi.org/10.1001/jamapsychiatry.2017.4614>
- Healthresearchfunding.org(2019) <https://healthresearchfunding.org/24-opiate-addiction-recovery-statistics/> 24 Shocking Opiate Addiction Recovery Statistics
- <https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder>
- Initiative, P. P. (n.d.). Minnesota incarceration pie chart 2023. www.prisonpolicy.org. Retrieved November 15, 2023, from https://www.prisonpolicy.org/graphs/correctional_control2023/MN_incarceration_2023.html
- Initiative, P. P. (n.d.). Minnesota profile. www.prisonpolicy.org/profiles/MN.html
- Initiative, P. P. (n.d.). New data on HIV in prisons during the COVID-19 pandemic underscore links between HIV and incarceration. [www.prisonpolicy.org](https://www.prisonpolicy.org/blog/2023/06/01/hiv_in_prisons). Retrieved November 15, 2023, from https://www.prisonpolicy.org/blog/2023/06/01/hiv_in_prisons
- Kakko et al. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. *Lancet* (2003) 361(9358):662-8.
- Korthuis PT, et al. HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial. *Addiction*. 2022 Jul;117(7):1961-1971. doi: 10.1111/add.15836. Epub 2022 Mar 2. PMID: 35129242; PMCID: PMC9314106.
- Krupitsky, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind placebo controlled, multicenter randomized trial. 2011; *Lancet* 377: 1506-13.
- Larochele, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. A cohort study. *Annals of Internal Medicine*. 169:3 (2018) 137-45.

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

50

50

REFERENCES: OUD MEDICATION

- Lim S;Cherian T;Katyal M;Goldfeld KS;McDonald R;Wiewel E;Khan M;Krawczyk N;Braunstein S;Murphy SM;Jalali A;Jeng PJ;MacDonald R;Lee JD; Association between Jail-Based Methadone or Buprenorphine Treatment for Opioid Use Disorder and Overdose Mortality after Release from New York City Jails 2011-17. *Addiction (Abingdon, England)*. U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/36305669/. Accessed 17 Jan. 2024.
- Mattick, RP, et al. (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Systematic Review*.
- Mattick, RP, et al. (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Systematic Review*.
- Macdonald C, Macpherson G, Leppan O, Tran LT, Cunningham EB, Hajarizadeh B, Grebely J, Farrell M, Attice FL, Degenhardt L. Interventions to reduce harms related to drug use among people who experience incarceration: systematic review and meta-analysis. *Lancet Public Health*. 2024 Sep;9(9):e684-e699. doi: 10.1016/S2468-2667(24)00160-9. PMID: 39214637.
- Metzger DS et al., Human Immunodeficiency Virus Seroconversion Among Intravenous Drug Users In- and Out-of-Treatment: An 18-Month Prospective Follow-Up. *Journal of Acquired Immune Deficiency Syndromes* 6, no. 9 (1993): 1049-56. <http://www.ncbi.nlm.nih.gov/pubmed/8340896>.
- MINNESOTA DEPARTMENT OF CORRECTIONS. (n.d.). Retrieved November 15, 2023, from https://mn.gov/doc/assets/Adult%20Prison%20Population%20Summary%207-1-2023_tcm1089-589994.pdf
- Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. *Cochrane Database Syst Rev*. 2011;2(11):CD001333. Published 2011 Apr 13. doi:10.1002/14651858.CD001333.pub4
- NIDA Medications to Treat Opioid Use Disorder Research Report Updated December 2021.
- Principals of Drug Addiction Treatment: A Research Based Guide." National Institute on Drug Abuse. Ed. NIDA International Program.

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

51

51

REFERENCES: OUD MEDICATION

- Quinn, et al. (2022). Naloxone administration among opioid-involved overdose deaths in 38 United States jurisdictions in the State Unintentional Drug Overdose Reporting System, 2019. *Drug and alcohol dependence*, 235, 109467.
- Rich, JD, et al. Continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. *Lancet* (2015) 386 (9991): 350-359.
- Schwartz RP, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. *Am J Public Health*. 2013 May;103(5):917-22. doi: 10.2105/AJPH.2012.301049. Epub 2013 Mar 14. PMID: 23488511; PMCID: PMC3670653
- Substance Abuse Mental Health Services Agency. Medications for Opioids Use Disorder: For Healthcare and Addiction Professionals, Policymakers, Patients and Families. Rockville MD SAMHSA Treatment Improvement Protocol (TIP) Series, No. 63 (2021).
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. (2020) *J Addict Med*14(2S Suppl 1):1-91. doi: 10.1097/ADM.0000000000000633. Erratum in: *J Addict Med*. 2020 May/June;14(3):267. PMID: 32511106.
- Treatment Research Institute (TRI), Ed. "Cost Utilization Outcomes of Opioid Dependence Treatment" *American Journal of Managed Care* 2011.
- Tsui, Ji et al., "Association of Opioid Agonist Therapy With Lower Incidence of Hepatitis C Virus Infection in Young Adult Injection Drug Users," *JAMA Internal Medicine* 174, no. 12 (2014): 1974-81. <http://archinte.jamanetwork.com/article.aspx?articleid=1918926>
- United States Department of Justice. Office of Justice Programs. Bureau of Justice Assistance. Guidelines For Managing Substance Withdrawal In Jails A Tool for Local Government Officials, Jail Administrators, Correctional Officers, and Health Care Professionals. June 2023
- Wakeman, SE, et al. (2020) Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. *JAMA Open Network*. 3 (2).
- Weimer MB, Herring AA, Kawasaki SS, Meyer M, Kleykamp BA, Ramsey KS. ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids. *J Addict Med*. 2023 Nov-Dec 01;17(6):632-639. doi: 10.1097/ADM.0000000000001202. Epub 2023 Jul 28. PMID: 37934520.
- www.druginserts.com

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

52

52

WHY MEDICATIONS FOR ALCOHOL USE DISORDER IS IMPORTANT?

Increased retention in treatment

Decreased drinking

Acamprosate

Naltrexone (oral and intramuscular)


Decreased cravings

Decreased healthcare costs

Disulfiram

HEALTH MANAGEMENT ASSOCIATES 53

53



54

DISULFIRAM FOR ALCOHOL USE DISORDER (AUD)

- » Approved decades ago; most recent data does NOT show overwhelming efficacy*
- » Once per day dosing
- » Inhibits multiple P450 and other liver enzymes
- » Drug Interactions: benzodiazepines, phenytoin, pimozone, tricyclic antidepressants (TCAs), warfarin, sulfonylureas, metronidazole, amoxicillin, isoniazid
- » Contraindications/precautions: alcohol use, hypersensitivity to rubber, severe coronary artery disease (CAD), cirrhosis, severe renal impairment, psychosis, depression, diabetes mellitus (DM), epilepsy
- » Extensively metabolized
- » Extensive list of side effects

Source: * McPheeters M, O'Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacik K, Coffey CP, Edlund MD, Bobashev G, Jonas DE. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. JAMA. 2023 Nov 7;330(17):1653-1665. doi: 10.1001/jama.2023.19761. PMID: 37934220; PMCID: PMC10639900.

HEALTH MANAGEMENT ASSOCIATES 55

55

NALTREXONE FOR ALCOHOL USE DISORDER

- » Few side effects
- » Drug Interactions: opioids
 - » No P450 interactions
- » Contraindications: severe acute hepatitis
- » Well studied in mild and moderate cirrhosis
- » Safe in mild renal disease

HEALTH MANAGEMENT ASSOCIATES 56


56

NALTREXONE EFFICACY

	Oral	Intramuscular
Reduced drinking days	Yes	Yes
Reduced heavy drinking days	Yes	Yes
Decreased opioid use	Yes	Yes
Decreased cravings	Yes	
Increased time to first drink	Yes	Yes
Treatment retention	Higher	Highest
Discontinuation of medication		Lower than oral
Decreased ED visits		Lower than oral
Decreased hospitalizations		Lower than oral
Decreased pharmacy cost		Lower than oral
Decreased nonpharmacy costs		Lower than oral

HEALTH MANAGEMENT ASSOCIATES 57

57



58

- ### ACAMPROSATE FOR ALCOHOL USE DISORDER
- » Effective
 - » Decreased quantity and frequency
 - » Increased retention in treatment and abstinence
 - » Three times per day dosing
 - » Drug Interactions: none
 - » Contraindications: severe renal impairment
 - » Dose reduce if someone has moderate renal impairment
 - » Few side effects
 - » No metabolism
- HEALTH MANAGEMENT ASSOCIATES 59

59

TIME FOR A POLL

Question:

Do you know anyone on medication for Alcohol Use Disorder?

A. Yes
B. No

HEALTH MANAGEMENT ASSOCIATES 60

60

REFERENCES: AUD MEDICATION

- » Ademar K, Loftén A, Nilsson M, Domi A, Adermark L, Söderpalm B, Ericson M. Acamprosate reduces ethanol intake in the rat by a combined action of different drug components. *Sci Rep.* 2023 Oct 19;13(1):17863. doi: 10.1038/s41598-023-45167-3. PMID: 37857829; PMCID: PMC10587117.
- » Kalk NJ, Lingford-Hughes AR. The clinical pharmacology of acamprosate. *Br J Clin Pharmacol.* 2014 Feb;77(2):315-23. doi: 10.1111/bcp.12070. PMID: 23278595; PMCID: PMC4014018.
- » McPheeters M, O'Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, Coffey CP, Edlund MD, Bobashev G, Jonas DE. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis. *JAMA.* 2023 Nov 7;330(17):1653-1665. doi: 10.1001/jama.2023.19761. PMID: 37934220; PMCID: PMC10630900.
- » Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism, Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.
- » Wong, J., Saver, B., Scanlan, J. M., Gianutsos, L. P., Bhakta, Y., Walsh, J., ... & Rudolf, V. (2020). The ASAM clinical practice guideline on alcohol withdrawal management. *Journal of Addiction Medicine, 14(3S)*, 1-72.

HEALTH MANAGEMENT ASSOCIATES

61

61

5-MINUTE STRETCH BREAK!




62

COUNSELING FOR CO-OCCURRING HIV & SUD

63

63

LEARNING OBJECTIVES: COUNSELING FOR CO-OCCURRING HIV & SUD



© 2020 Health Management Associates, Inc. All Rights Reserved

HEALTH MANAGEMENT ASSOCIATES


64

64

WHY IS IT IMPORTANT TO ADDRESS SUD IN PERSONS WITH HIV?

Substance use accelerates the progression of HIV

- » Increases viral load
- » Increases likelihood of AIDs related morbidity (even when adherent to antiretroviral medications)
- » Decreases medication adherence



Sources: Dash, 2015; Schaffer 2017; Strazza 2011; Dahal 2015; Andriote 2012; NIDA 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/>
Photo Source: National Cancer Institute on Unsplash

HEALTH MANAGEMENT ASSOCIATES


65

65

WHY IS IT IMPORTANT TO ADDRESS SUD IN PERSONS WITH HIV?

Addictive substances weaken the blood brain barrier

- » Allowing HIV to more easily enter the brain
- » Allows infection and damage to nerves and supporting cells (glia)
- » Triggers release of neurotoxins
- » Can lead to dementia
 - » 50% of people with HIV have neurocognitive disorders



Sources: Dash, 2015; Schaffer 2017; Strazza 2011; Dahal 2015; Andriote 2012; NIDA 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders/>
Photo Source: Mitad Fakurian on Unsplash


HEALTH MANAGEMENT ASSOCIATES

66

66

HIV TESTING

- » 19% of 15-44yo in the United States were tested for HIV in the past year
- » Only one-third of SUD programs offer onsite HIV testing



Sources: NIDA 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders>
Substance Abuse and Mental Health Services Administration. (2021). Treating Substance Use Disorders Among People with HIV. Advisory
Photo Source: Testalize.me on Unsplash

HEALTH MANAGEMENT ASSOCIATES

67

67

HIV TESTING RECOMMENDATIONS

- ✓ SAMHSA recommends universal HIV testing for
 - » Persons 15-65yo (and all pregnant persons)
 - » Younger and older persons at increased risk, such as:
 - » People who inject drugs
 - » People who have condomless sex
 - » People who participate in commercial sex work
- ✓ US Preventative Task Force Rating A
 - » Requires Medicare and Medicaid to pay for testing
 - » Rapid tests are available- results within 30 minutes
 - » Provide pre and post test counseling- reviewed in other talks

Sources: NIDA 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders>
Substance Abuse and Mental Health Services Administration. (2021). Treating Substance Use Disorders Among People with HIV. Advisory.

HEALTH MANAGEMENT ASSOCIATES

68

68

STTR MODEL OF CARE

- » Testing persons who inject drugs every 6 months is cost effective
- » **Recommendation:** Inpatient and outpatient mental health settings should offer routine opt out testing to improve case finding




Chart review compared to blood samples from 2 inpatient psychiatric units:
21% of patients with HIV positive blood samples did not have documentation of infection in medical record

Sources: NDA 2021 <https://www.dhs.gov/publication/research-reports/communities-substance-use-disorders>
Holtzman AB, Fairman PG, Sison SL, Tajal E, Murren JT. Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States. *J Acquir Immune Defic Syndr*. 2009; 51(1):102-108. doi:10.1097/QAI.0b013e3181690808
Gallay CL, Peckerton SD, Patel AE. CDC recommendations for opt-out testing and reactions to unanticipated HIV diagnoses. *AIDS Patient Care STDS*. 2008; 22(3):189-93. doi:10.1089/apc.2007.0144. PMID: 1829754. PMID: 18427814
Branson BM, Handfield HL, Lampe MA, Jensen RS, Taylor AW, Lynn SB, Clark JE. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep*. 2008; 57(23):505-11. PMID: 18698943.
Rutbard AB, Blank MB, Saab JP, et al. Prevalently Undetected Metabolic Syndromes and Infectious Diseases Among Psychiatric Inpatients. *Psychiatric Services*. 2009;60(4):534-537.

HEALTH MANAGEMENT ASSOCIATES 69

TIME FOR A POLL

Question:


In your organizations, do you test for HIV?

- A. Yes
- B. No
- C. I Don't Know

© 2025 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 70

EPIDEMIOLOGY- HIV & MENTAL HEALTH

- » Up to 70% of people living with HIV have a history of trauma
- » 54% of people living with HIV have post-traumatic stress disorder (PTSD)
- » People living with HIV are twice as likely to develop depressive symptoms compared to those at risk but who are not living with HIV
- » People living with HIV experience higher rates of depression than the general population
- » Key feature of depression, as compared to adjustment disorder or side effects from medication, is loss of pleasure




Sources: Kessler, R.C. 2005, Andriote, JM. 2012, Gaynes, B.N. 2008, Blank M.B.2013

HEALTH MANAGEMENT ASSOCIATES

EPIDEMIOLOGY- HIV & MENTAL ILLNESS

- » Twenty-two percent (22%) of people with HIV have depression
 - » Of those 78% **ALSO** have an anxiety disorder
 - » Of those 61% **ALSO** have an SUD
- » Six percent (6%) of people with HIV have schizophrenia, as compared to 1% of the general population
- » Those with schizophrenia are **1.5x** as likely to contract HIV
- » Those with affective disorders were **3.8x** as likely to contract HIV




Sources: Kessler, R.C. 2005, Andriote, JM. 2012, Gaynes, B.N. 2008, Blank M.B.2013

HEALTH MANAGEMENT ASSOCIATES 72

SUD, HIV AND MENTAL ILLNESS

- » 54% people with HIV report moderate to high-risk cannabis use
- » 40% people with HIV report moderate to high-risk drinking
- » 12% people with HIV report moderate to high-risk cocaine
- » 11% people with HIV reported moderate to high risk of amphetamine use




Sources: Staruss, S.M. 2009
Andriote, JM. 2012
Dawson Rose 2017

© 2025 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 73

73

COUNSELING: COPING WITH AN HIV DIAGNOSIS

- » Coping with the diagnosis of HIV
 - » is a form of grieving
 - » is different from having a major depressive episode
 - » may require treatment
 - » support or psychotherapy
 - » will not respond to antidepressants



Sources: Andriote, JM. 2012 <http://www.waldmap.com/news/aug-2021/hardest-outcome-all-hiv-and-suicide>
Photo Source: LinkedIn Sales Solutions on Unsplash

© 2025 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 74

74

COUNSELING RECOMMENDATIONS

1. Don't try to solve or fix things, but....
 - Housing is important
 - Social support is important
 - Medical care is important
 - These things helps establish a sense of control over one's life
2. Don't minimize someone's feelings
3. Don't tell people to pull themselves together
4. Listen... for risks and for talk of the future

Sources: Andriote, JM. 2012 <http://www.waldmap.com/news/aug-2021/hardest-outcome-all-hiv-and-suicide>

© 2025 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 75

75

CONSIDERATIONS FOR MENTAL HEALTH TREATMENT OF INDIVIDUALS WITH HIV AND SUD

- » Major Depression, among those living with HIV, responds to the same treatments:
 - » Evidence-based psychotherapy
 - » Evidence-based medications
 - » Medication and psychotherapy
- » As with other conditions, keep drug-drug interactions in mind
- » Depression & bipolar disorder can make medication adherence challenging

ANTIDEPRESSANT TREATMENT OF DEPRESSION RESULTS IN LOWER HEALTHCARE COSTS

- » Persons with bipolar disorder and HIV are more likely to have unprotected intercourse with HIV negative partners
- » The risk of suicide is higher for those with HIV (at all stages) as compared to the general population

Sources: McGlinch 2020, Andriote, JM. 2012 & Blank MB 2013

© 2025 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 76

76

SUD TREATMENT FOR THOSE LIVING WITH HIV

- » Cognitive Behavioral Therapy (CBT) & Motivational Interviewing (MI)
 - » Reduce drug use
 - » Reduce high risk sexual behaviors
 - » Reduce viral load
 - » Improve adherence to antiretrovirals

SUD Treatment is HIV Prevention!

Source: NIDA 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders>

HEALTH MANAGEMENT ASSOCIATES 77

77

SUD TREATMENT FOR THOSE LIVING WITH HIV

- » Opioid Use Disorder
 - » Methadone and buprenorphine are associated with a 54% reduction in risk of HIV infection in persons who inject drugs
- » Alcohol Use Disorder (AUD)
 - » Behavioral and medication for AUD
 - » Increase intensity of behavioral treatment led to greater improvements than lower intensity behavioral treatments among those with detectable viral loads
 - » AUDIT C scores improved
 - » Viral loads, CD4
 - » Adherence
 - » Medication for AUD was associated with
 - » Increased CD4 among those with detectable viral loads
 - » Increased adherence among those with detectable and undetectable viral loads

Source: NIDA 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders>; McGinnis KA, et al. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. Drug Alcohol Depend. 2020 Dec 1;217:108272. doi: 10.1016/j.drugalcdep.2020.108272. Epub 2020 Sep 11. PMID: 32971391; PMCID: PMC7757793.

HEALTH MANAGEMENT ASSOCIATES 78

78

EPIDEMIOLOGY- SUICIDALITY & HIV

Suicide

- » 3rd most common cause of death in 15-29yo women
- » 4th most common cause of death in 15-29yo men
- » No relationship to income
- » A life-threatening illness is a one of the most strongly predictive factors for completed suicide
- » Suicide rate in the first year after an HIV diagnosis is 5x the rate in the general population. Suicide in the first year after an HIV diagnosis accounts for 40% of all suicide in persons with HIV.

Suicide Attempt Rate

People living with HIV: 16%

General Population: 3%

Suicidal Ideation Rate

People living with HIV: 23%

General Population: 9%

Sources: <http://www.waldmap.com/news/aug-2021/hardest-outcome-all-hiv-and-suicide> <https://www.health.state.mn.us/people/syringe/suicide.pdf>

HEALTH MANAGEMENT ASSOCIATES 79

79

TIME FOR A POLL

Question:


People who talk about suicide, do not have attempts or complete suicide.

A. True
B. False

HEALTH MANAGEMENT ASSOCIATES 80

80

RISK FACTORS FOR SUICIDE



Suicidal Ideation Risk Assessment
STEPS AND RESOURCES FOR EXPLORING THOUGHTS OF SUICIDE

- Trauma
- Triggering event- stressor
- Ideation & past behavior
- Health-medical, mental and substance
- Purposeless, hopeless
- Poor sleep
- Mood, anxiety, anger, withdrawal
- Reckless, impulsive


Sources: <https://www.health.state.mn.us/people/syringe/suicide.pdf>

HEALTH MANAGEMENT ASSOCIATES

81

ASSESSMENT FOR SUICIDALITY

- » Which factors can be modified to reduce risk?
 - » Opportunities for healing
 - » Reduce harms
- » Protective factors
 - » Connectedness
 - » Support
 - » Skills- problem solving, coping, healing



Sources: <https://www.health.state.mn.us/people/syringe/suicide.pdf>
Photo Source: Glenn Carstens-Peters on Unsplash

HEALTH MANAGEMENT ASSOCIATES

82

ASSESSMENT RECOMMENDATIONS

1. Be mindful that protective factors are unique to each person
2. Use the person's language
3. Ask open ended questions such as:
 - » What are things that keep you safe?
 - » When this occurred in the past what has stopped you?
 - » Who are the people who lift your spirits?
 - » What activities lift your spirits?
 - » What would you like to develop within yourself in the future?
4. Try to identify protective factors that can be enhanced

Sources: <https://www.health.state.mn.us/people/syringe/suicide.pdf>

HEALTH MANAGEMENT ASSOCIATES

83

INTEGRATED PRIMARY HIV & BEHAVIORAL HEALTH CARE

Benefits of Integration

- » Increases likelihood of follow through on referrals
- » Improve physical health outcomes
- » Increased savings in healthcare cost
- » Reduce emergency room use

Ryan White HIV/ AIDS Treatment Extension Act 2009

- » Aligns with HHS guidelines
- » Mandates include:
 1. Universal depression and SUD screening
 - » MH screening rates currently are between 80%-100%
 - » SUD screening rates currently are much lower
 2. Establishment of follow up plan

Sources: <https://www.health.state.mn.us/people/syringe/suicide.pdf>

HEALTH MANAGEMENT ASSOCIATES

84

REFERENCES:

- Andriote, J. APA Fact Sheet HIV mental health treatment issues HIV and clinical depression 2012
- Andriote. HIV and Clinical Depression APA Fact Sheet 2012, Arlington VA
- Blank MB, Himelthoch S, Walkup J, Eisenberg MM. Treatment considerations for HIV-infected individuals with severe mental illness. *Curr HIV/AIDS Rep.* 2013 Dec;10(4):371-9. doi: 10.1007/s11904-013-0179-3. PMID: 24158425
- Branson BM, et. al. Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. *MMWR Recomm Rep.* 2006 Sep 22;55(RR-14):1-17; quiz CE1-4. PMID: 16988643.
- Dahal S, Chitti SV, Nair MP, Saxena SK. Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDS. *Front Microbiol.* 2015 Sep 8;6:931. doi: 10.3389/fmicb.2015.00931. PMID: 26441868
- Dash S, Balasubramaniam M, Villalta F, Dash C, Pandhare J. Impact of cocaine abuse on HIV pathogenesis. *Front Microbiol.* 2015 Oct 20;6:1111. doi: 10.3389/fmicb.2015.01111. PMID: 26539167
- Galletly CL, Pinkerton SD, Petroll AE. CDC recommendations for opt-out testing and reactions to unanticipated HIV diagnoses. *AIDS Patient Care STDS.* 2008 Mar;22(3):189-93. doi: 10.1089/apc.2007.0104. PMID: 18290754; PMCID: PMC2728134.
- Gaynes BN, Pence BW, Eron JJ Jr, Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. *Psychosom Med.* 2008 May;70(4):505-11. doi: 10.1097/PSY.0b013e31816aa0cc. Epub 2008 Mar 31. PMID: 18378865
- Hutchinson AB, Farnham PG, Sansom SL, Yaylali E, Mermin JH. Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States. *J Acquir Immune Defic Syndr* 1999. 2016;71(3):323-330. doi:10.1097/QAI.0000000000000838.
- Kessler RC, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry.* 2005 Jun;62(6):593-602. doi: 10.1001/archpsyc.62.6.593. Erratum in: *Arch Gen Psychiatry.* 2005 Jul;62(7):768. PMID: 15939837.

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

85

85

REFERENCES:

- McGinnis KA, et. al. Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: A longitudinal analysis. *Drug Alcohol Depend.* 2020 Dec 1;217:108272. doi: 10.1016/j.drugalco.2020.108272. Epub 2020 Sep 11. PMID: 32971391; PMCID: PMC7757793.
- NIDA 2021 <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders>
- NIDA, 2021. <https://www.drugabuse.gov/publications/research-reports/common-comorbidities-substance-use-disorders>
- Rothbard AB, Blank MB, Staab JP, et al. Previously Undetected Metabolic Syndromes and Infectious Diseases Among Psychiatric Inpatients. *Psychiatric services.* 2009;60(4):534-537.
- Schaefer CP, Tome ME, Davis TP. The opioid epidemic: a central role for the blood brain barrier in opioid analgesia and abuse. *Fluids Barriers CNS.* 2017 Nov 29;14(1):32. doi: 10.1186/s12987-017-0080-3. PMID: 29183383
- Strauss SM, Rindskopf DM. Screening patients in busy hospital-based HIV care centers for hazardous and harmful drinking patterns: the identification of an optimal screening tool. *J Int Assoc Physicians AIDS Care (Chic).* 2009 Nov-Dec;8(6):347-53. doi: 10.1177/1545109709350509. Epub 2009 Oct 22. PMID: 19850861
- Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR. Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. *Brain Res.* 2011 Jul 5;1399:96-115. doi: 10.1016/j.brainres.2011.05.015. Epub 2011 May 14. PMID: 21641584
- Substance Abuse and Mental Health Services Administration and Health Resources and Services Administration, The Case for Behavioral Health Screening in HIV Care Settings. HHS Publication No. SMA-16-4999. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2016.
- Substance Abuse and Mental Health Services Administration. (2021). Treating Substance Use Disorders Among People with HIV. Advisory.

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

86

86

STIMULANT USE

© 2025 Health Management Associates, Inc. All Rights Reserved.

87

LEARNING OBJECTIVES:
STIMULANT USE AND PERSONS WHO ENGAGE IN CHEMSEX

- | | | |
|---|--|---|
| I
List at least 5 risks associated with methamphetamine usage | II
Define and identify at least 2 benefits of contingency management | III
Identify at least 3 risk behaviors of persons who engage in Chemsex |
|---|--|---|

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

88

88

WHAT ARE STIMULANTS?


- >> Cocaine
- >> "Psychostimulants with abuse potential"
 - >> Mahuang, ephedra & khat- plants
 - >> Pseudoephedrine, ephedrine & cathinone & cathine
 - >> "Bath salts" (synthetic man made cathinones)
 - >> Amphetamine (synthetic)
 - >> Methamphetamine
 - >> Amphetamine
 - >> MDMA/ecstasy = Molly = methylenedioxy-methamphetamine
 - >> Methylphenidate = Ritalin™
 - >> Methylxanthines (naturally occurring)
 - >> Caffeine (coffee)
 - >> Theophylline (tea)
 - >> Theobromine (chocolate)



HEALTH MANAGEMENT ASSOCIATES

DRUG SEIZURES IN MINNESOTA

VCET Drug Seizures: All in 2019
Note: All amounts listed in grams, except for prescriptions which are listed in doses




Drug Category	Amount (Grams)
Marijuana & Concentrates	765,752
Meth	656,694
Cocaine	45,275
Prescriptions	31,138
Heroin	22,594

Source: Minnesota Department of Public Safety, Violent Crime Enforcement Teams (VCET) Dashboard
<https://dps.mn.gov/divisions/op/statistical-analysis-center/Pages/vcet-dashboards.aspx>

HEALTH MANAGEMENT ASSOCIATES

ADMISSIONS TO SUD TREATMENT: MN



Year	Alcohol	Methamphetamine	Injection Drug Use	Heroin	Other Opiates
2011	24,500	4,000	4,000	3,000	2,000
2012	23,500	4,500	5,000	4,000	3,000
2013	22,500	5,500	6,000	5,000	3,500
2014	22,000	7,500	7,000	6,000	3,500
2015	21,500	9,500	8,000	7,000	3,500
2016	21,000	12,000	10,000	8,000	3,500
2017	21,500	14,000	11,000	8,000	3,000
2018	21,000	15,500	11,000	7,000	2,500
2019	22,500	16,500	13,500	7,000	2,000
2020	20,500	14,500	10,000	6,500	2,000
2021	22,000	16,000	10,500	6,500	3,500


Download data

Source: Minnesota Department of Human Services, Drug and Alcohol Abuse Normative Evaluation system (DAANES)

HEALTH MANAGEMENT ASSOCIATES

COCAINE USE NATIONALLY & LOCALLY


Cocaine Use in Past Year Among Individuals Aged 12 or Older, by Geographic Area




Year	Minnesota	Midwest	United States
2002	2.5%	2.5%	2.5%
2003	2.4%	2.4%	2.4%
2004	2.3%	2.3%	2.3%
2005	2.3%	2.3%	2.3%
2006	2.3%	2.3%	2.3%
2007	2.3%	2.3%	2.3%
2008	2.1%	2.1%	2.1%
2009	1.8%	1.8%	1.8%
2010	1.3%	1.3%	1.3%
2011	1.3%	1.3%	1.3%
2012	1.4%	1.4%	1.4%
2013	1.4%	1.4%	1.4%
2014	1.4%	1.4%	1.4%
2015	1.5%	1.5%	1.5%
2016	1.8%	1.8%	1.8%
2017	2.4%	2.4%	2.4%
2018	2.1%	2.1%	2.1%
2019	2.1%	2.1%	2.1%
2020	1.7%	1.7%	1.7%
2021	1.7%	1.7%	1.7%

Source: <https://dataools.samhsa.gov/saes/state>


HEALTH MANAGEMENT ASSOCIATES




93




94




95



96



97



98

IN THE CHAT BOX PLEASE ANSWER THIS QUESTION:

Do you prefer:


Coffee

Tea

Chocolate

Soda

I refuse to pick just one



99

MEDICINAL USES FOR STIMULANTS

- » Cocaine- used as a vasoconstrictor & numbing agent
- » "Psychostimulants with abuse potential"
 - » Ephedra- made into pseudoephedrine and used for allergies and colds
 - » Khat used for depression, obesity, fatigue in middle east
 - » Amphetamines are used for obesity, narcolepsy & Attention Deficit Hyperactivity Disorder (ADHD)
 - » Methylxanthines
 - » Caffeine (coffee)
 - » Theophylline (tea) used for asthma
 - » Theobromine (chocolate)





Amphetamine dosing:
ADHD 2.5 mg/day to 70mg/ day
Narcolepsy 5 mg/day to 60 mg/day

Methamphetamine dosing:
ADHD approved but not commonly used
5 mg/day to 25 mg/ day

Illicit use of amphetamines/ methamphetamines up to 1 g / day

100

SOME CONSEQUENCES ARE DUE TO MODE OF CONSUMPTION

- » Smoking 
 - » Burned lips
 - » Throat problems
 - » Lung problems- acute (50% of those who smoke cocaine) and chronic 
- » Injection (unsafe practices) 
 - » Skin & heart infections
 - » Hepatitis or HIV
- » Snorting 
 - » Sinus infections
 - » Holes in nasal septum
 - » Nosebleeds
 - » Hoarseness

NOTE:
There is cross tolerance from one class of stimulants to another

HEALTH MANAGEMENT ASSOCIATES 101

101

EFFECTS DEPENDENT UPON MODE OF CONSUMPTION

Drug Reaches Brain	}	<ul style="list-style-type: none"> ▪ Smoking- 6-8 seconds ▪ Injection- seconds ▪ Snorting- 15 minutes ▪ Oral-45 minutes
Half-Life	}	<ul style="list-style-type: none"> ▪ Cocaine .75-1.5h ▪ Bath Salts (Cathinone) .7-2.3 hours ▪ Amphetamine 7-34 hours ▪ Methamphetamines 6-15 hours

HEALTH MANAGEMENT ASSOCIATES 102

102

TIME FOR A POLL

Have you had trouble retaining patients with stimulant use disorders in treatment?

A. Yes

B. No

HEALTH MANAGEMENT ASSOCIATES 103

103

STIMULANTS EFFECTS ON BRAIN CHEMISTRY

Cocaine: Reuptake Blocker
INDIRECT agonist of
+ dopamine
+ norepinephrine
+ serotonin

BLOCKS
+ neurotransmitters reuptake
+ sodium channels

Amphetamines: Releaser
INDIRECT agonist of
+ dopamine
+ norepinephrine
+ serotonin

INHIBITS
+ metabolism of neurotransmitters
+ vesicular storage
+ reverses reuptake




Photo Source: <https://www.drugabuse.gov/news-events/hida-notes/2017/03/impacts-drugs-neurotransmission>

HEALTH MANAGEMENT ASSOCIATES 104

104

ACUTE EFFECTS OF STIMULANTS

- Increased
 - Alertness/vigilance, concentration, mental acuity
 - Energy, movement
 - Sensory awareness & sexual desire
 - Self confidence, grandiosity, anxiety, irritability, paranoia
 - Heart rate & blood pressure, irregular heartbeat, vasoconstriction
 - Breathing rate, temperature, pupil size & blood sugar
 - Electrical activity, seizures
- Euphoria
- Abnormal bowel and bladder function

Toxic effects on muscles including Muscle , tremors, stereotypy (i.e., ritualistic movements)

Decreased
Brain blood flow & glucose metabolism
Appetite & sleep
Judgment & complex multi-tasking

Cardiovascular effects
Heart attacks
Arrhythmias
Severe hypertension
Strokes

Increased potential for violence and psychosis

HEALTH MANAGEMENT ASSOCIATES 105

105

STIMULANT INTOXICATION: TREAT THE PRESENTING SIGN/SYMPOM

Overdose:
Seek immediate medical attention for:

- Hypertensive (HTN) crisis
- Cardiac arrhythmias
- Heart attack
- Stroke – Act F.A.S.T.*
- Psychosis

Treatment of Overdose
Treat HTN with alpha and/ or beta blockers
Treat arrhythmias with anti-arrhythmics
Treat vasoconstriction with nitroglycerin

BH interventions for Overdose
Talk down the client in a calm environment
Treat agitation with benzodiazepine
Treat psychosis with antipsychotics

* Facial drooping, Arm weakness, Speech difficulty, Time to call 9-1-1

HEALTH MANAGEMENT ASSOCIATES 106

106

LONG-TERM MENTAL EFFECTS OF ILLICIT STIMULANTS

- » Tolerance to euphoria and appetite suppression
- » Loss of ability to concentrate & severe memory loss
- » Loss of ability to feel pleasure without drug
- » Dopamine depletion after repeated use of addictive substances to intoxication
- » Paranoia and psychosis (hallucinations & delusions)
- » Insomnia and fatigue
- » Irritability and anger
- » Depression (suicidal ideation)
- » Impulsive, risky sexual behavior

* Use of stimulants in doses approved by FDA for treatment of medical conditions do not result in these effects

HEALTH MANAGEMENT ASSOCIATES 107

107

LONG TERM PHYSICAL EFFECTS OF ILLICIT STIMULANTS

- » Dry mouth, severe dental decay & gum problems
- » Bruxism (tooth grinding)
- » Weight loss
- » Increased sweating; oily skin
- » Skin lesions from injection & formication (leading to skin picking)
- » Headaches
- » Movement disorders and seizures
- » Strokes (bleeding into the brain) & heart attacks

- » Irregular heart beats
- » Cardiomyopathy
- » Kidney & liver failure
- » Pulmonary hypertension
- » Damaged brain cells
- » Neonatal effects

HEALTH MANAGEMENT ASSOCIATES 108

108

STIMULANTS AND PREGNANCY

- » Pregnancy may increase risk of cardiovascular events
- » Preterm labor
- » Earlier gestational age at delivery
- » Low birth weight
- » Small for gestational age
- » Strokes in utero
- » Secreted in breast milk

Child:
 Dysregulated behavior, growth, inhibitory control, attention and abstract reasoning, but these effects appear to be related to gestational age at delivery, psychiatric disorders, other prenatal exposures and quality of postnatal environment. *
 Anxiety, depression at 3-year-old **
 Worse cognitive function at 7-year-old **

Source: Gouin 2011- cocaine; Kalatzopoulos, 2018
 *Smith, M. C., Metz, T. D., & Gordon, A. J. (2019). Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. *Clinical obstetrics and gynecology*, 62(1), 168-184. <https://doi.org/10.1097/GRF.0000000000000418>
 **Deruf et al. 2007

HEALTH MANAGEMENT ASSOCIATES 109

109

STIMULANT USE IN PREGNANT PEOPLE

- » Pregnancy
 - » During pregnancy stimulant use is more common than opioid use
 - » Cannabis is the most used substance during pregnancy
 - » Followed by stimulants
- » Homelessness and sexual violence predict stimulant use in women...
 If Post-traumatic Stress Disorder (PTSD) is present
 - » Integrated treatment is more effective for co-occurring disorder (COD)

Sources:
 - Center for Behavioral Health Statistics Quality. 2015 National survey on drug use and health: Detailed tables In:2016
 - Riley, ED. Risk factors for stimulant use among homeless and unstably housed adult women. *Drug Alcohol Depend.* 2015 August 1; 153: 173-179. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510017/pdf/nlm664947.pdf>
 - Rudless LM, Hien DA, Hu M, Campbell ANG. Associations Between Post-traumatic Stress Symptoms, Stimulant Use and Treatment Outcomes: A Secondary Analysis of NIDA's Women and Trauma Study. *Amer J on Addictions.* Vol 23(1): 90-95. Jan-Feb 2014. <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1521-0391.2013.12068.x>

HEALTH MANAGEMENT ASSOCIATES 110

110

CESSATION FROM STIMULANTS

- Acute withdrawal:
 - 4 days
 - No medication recommended
- Symptoms
 - Increased appetite
 - Increased sleep & dreaming
 - Decreased activity & energy
 - Depression & anhedonia
 - Decreased concentration
 - Craving

- Protracted withdrawal
 - Up to 10 weeks
 - No medication recommended
- Lingering effects on the brain; may be permanent
 - Psychosis
 - Movement Disorders
 - Cognitive Issues

Handout: Stimulant Withdrawal: Monitoring & Treatment
<https://addictionfreeca.org/ffpnseg8rpkqg>

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 111

111

AMPHETAMINES AND COGNITIVE IMPAIRMENT

- » Two-thirds of people with amphetamine use disorder have cognitive impairment
- » Impairment is "associated" with:
 - » Older age
 - » Earlier onset of use
 - » Longer duration of use
 - » Greater frequency of use
- » May limit ability to follow through on treatment

- » Damage cell structures
 - » Mitochondria in neurons & microglia
- » Damage DNA
 - » Chromosomal alterations
- » Inflammation of microglia
- » Disruption of blood brain barrier
 - » Inflammatory markers in peripheral blood
- » Cell death

Source: Paulus, M (2020) Neurobiology, clinical presentation, and treatment of methamphetamine use disorder a review. *JAMA Psychiatry* 77(9): 959-66.

HEALTH MANAGEMENT ASSOCIATES 112

112

AMPHETAMINES AND LINGERING EFFECTS ON BRAIN

- » May be permanent even with prolonged abstinence
 - » Attention
 - » Memory
 - » Learning efficiency
 - » Visual- spatial processing
 - » Processing speed
 - » Psychomotor speed
 - » Executive dysfunction

Cognitive Impairment
Impairs ability to engage in treatment due to trouble

- Sequencing events to get to treatment
- Remembering what is taught
- Applying what is taught

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 113

113

TREATMENT OF STIMULANT USE DISORDER

- » Harm Reduction
 - » Educational materials on psychological & physical effects
 - » Fentanyl test strips
 - » Syringe Exchange/distribution & other clean injection supplies
 - » Naloxone and overdose prevention education
 - » Quiet rooms to come down
 - » Showers & antibiotics for infection prevention & treatment
 - » Condoms & info on safe sex practices
 - » Water for hydration
 - » Toothpaste and toothbrush




Photo sources: Reproductive Health Supplies Coalition, Sara Groblechner, and Giorgio Trovato on Unsplash

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 114

114

TREATMENT OF STIMULANT USE DISORDER: SAMHSA EVIDENCE BASED RESOURCE GUIDE

- » Motivational Interviewing (MI)
 - » Decreased days of stimulant use & amount of stimulant used/ day
- » Cognitive Behavior Therapy (CBT)
 - » Decreased quantity of stimulant use & frequency/ week
 - » Decreased risky sexual behaviors
- » Community Reinforcement Approach- see next slide
- » Contingency Management- see next slide

STRONG EVIDENCE FOR THESE AS INDIVIDUAL INTERVENTIONS OR IN COMBINATION APPROACHES

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 115

115

TREATMENT OF STIMULANT USE DISORDER

- » Community Reinforcement Approach (CRA)
 - » Decreased addiction severity
 - » Decreased drug use (weeks of use, frequency/week, \$/week)
 - » Increased cocaine abstinence
- » Contingency Management (CM): Strongest Effect Size
 - » Decreased
 - » days of stimulant use
 - » stimulant cravings
 - » HIV risk behaviors
 - » Studies Veterans Administration National Rollout
 - » Pre-CM: compared to 42% completed 2 sessions in 1 year
 - » Post-CM Implementation: 50% completed 14 sessions in 12 week
 - » 92% of >69,000 toxicology tests negative

Sources: SAMHSA Opioid SAM (2015) Warner & DePhillips (2020)

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 116

116

HOW DOES CONTINGENCY MANAGEMENT WORK?

- » Select objective target behavior (abstinence)
 - » Define the behaviors
 - » Attendance at clinic (group appt, urine)
 - » Abstinence from DOC? all illicit drugs? prescribed drugs? alcohol?
- » Provide immediate, consistent, tangible, desired rewards for target behavior
- » Escalate size of reward for consistent behavior
- » When target behavior does not occur
 - » Withhold the reward
 - » Reset size of reward for next occurrence of behavior
- » Example: Fishbowl Method
 - » 250 good job cards/gifts
 - » 209 vouchers for \$1; 40 for \$20; 1 for \$100

REMEMBER:
Measure objectively & frequently
Don't set the bar too high or low

Reinforcement totaling \$80 = treatment as usual.
Reinforcements of \$240 improves outcomes.
Petry 2004

SAMHSA Advisory Jan. 2025
Grant Funds up to \$750/year/patient For CM for SUD.

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 117

117

IN THE CHAT BOX PLEASE ANSWER THIS QUESTION:

Do you have a Contingency Management Program?

Yes
No



Photo Source: Jasper Garratt on Unsplash
HEALTH MANAGEMENT ASSOCIATES © 2020 Health Management Associates, Inc. All Rights Reserved.

118

WHAT TREATMENTS HAVE BEEN TRIED FOR STIMULANT USE DISORDER?

- » Cocaine & amphetamines not consistently effective
- » Antidepressants: SSRIs and tricyclic antidepressants not effective
- » Bupropion: risk of seizures; 5 failed trials for amphetamine use disorder *
- » Mirtazapine: risk of weight gain; single small study + for amphetamine use disorder in men who have sex with men
- » Treatment of co-occurring Opioid Use Disorder (OUD)
- » Opioid agonists: increased dose of buprenorphine or methadone shows decreased cocaine use generally
- » Naltrexone: + results in multiple small studies amphetamine use disorder and cocaine use disorder *
- » Antiseizure medications: Topiramate (risks); + one or two small studies in amphetamine use disorder

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES * See next slide 119

119

WHAT TREATMENTS HAVE BEEN TRIED FOR STIMULANT USE DISORDER?

https://downloads.asam.org/steffinity-production-blobx/docs/default-source/quality-science/stud_guideline_document_final.pdf?sfvrsn=21094b38_1



The ASAM/AAAP
CLINICAL PRACTICE GUIDELINE ON THE Management of Stimulant Use Disorder

There are NO FDA approved medications for stimulant use disorders. Best Practices and Standards of Care do NOT endorse medication for stimulant disorders, by prescribers who are not experienced in addiction medicine.

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 120

120

WHAT'S ALL THE FUSS ABOUT?

- » New England Journal of Medicine article 2021
- » 400 adults with methamphetamine use disorder
- » Bupropion 450mg per day + placebo or bupropion 450mg per day + extended-release naltrexone 380mg IM q 3w (XR NTX)
- » 6-week study
- » Response defined as 3 of 4 toxicology tests negative for methamphetamines
- » 14% of patients on Bupropion + XR NTX responded vs 3% on Bupropion + placebo
- » Buprenorphine vs. placebo has a 21% difference for negative tox screen

This is a 6-week study and has NOT been replicated yet. Only 11% increased response over placebo. Compare this to the EXCELLENT outcomes from psychosocial treatments.

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

* See next slide

121

121

REFERENCES: STIMULANT USE

- ATTC Network. (2024). SAMHSA guidance for implementation of contingency management training and technical assistance - Addiction technology transfer center (ATTC) network. ATTC Network. https://attcnetwork.org/products_and_resources/samhsa-guidance-for-implementation-of-contingency-management-training-and-technical-assistance/
- Baicy, K., & London, E. D. (2007). Corticolimbic dysregulation and chronic methamphetamine abuse. *Addiction*, 102, 5–15. doi:10.1111/j.1360-0443.2006.01777.x
- Bolivar HA, Klemperer EM, Coleman SRM, DeSarno M, Skally JM, Higgins ST. Contingency Management for Patients Receiving Medication for Opioid Use Disorder: A Systematic Review and Meta-analysis. *JAMA Psychiatry*. 2021 Oct 1;78(10):1092-1102. doi: 10.1001/jamapsychiatry.2021.1969. Erratum in: *JAMA Psychiatry*. 2022 Jan 26; PMID: 34347030; PMCID: PMC8340014.
- California Department of Public Health. (2020). California Opioid Overdose Surveillance Dashboard. <https://skylab.cdph.ca.gov/ODdash/>
- CDC/NCHS, National Vital Statistics System, Mortality. CDC WONDER, Atlanta, GA: US Department of Health and Human Services, CDC; 2020. <https://wonder.cdc.gov/>
- Chester, N., Mottram, D. R., Reilly, T., & Powell, M. (2004). Elimination of ephedrine in urine following multiple dosing: the consequences for athletes, in relation to doping control. *British journal of clinical pharmacology*, 57(1), 62–67.
- DeFulio A, Rzesutek MJ, Furgeson J, Ryan S, Rezanian S. A smartphone-smartcard platform for contingency management in an inner-city substance use disorder outpatient program. *J Subst Abuse Treat*. 2021 Jan;120:108188. doi: 10.1016/j.jsat.2020.108188. Epub 2020 Nov 2. PMID: 33298295.
- Foulds, J., & Young, J. T. (2019). Pharmacotherapy for incarcerated people with a history of violence: Response to commentary by Schofield et al. *Australian & New Zealand Journal of Psychiatry*, 54(1), 106–107. doi:10.1177/0004867419885175
- Gouin, K., Murphy, K., & Shah, P. S. (2011). Effects of cocaine use during pregnancy on low birthweight and preterm birth: systematic review and metaanalyses. *American Journal of Obstetrics and Gynecology*, 204(4), 340.e1–340.e12. doi:10.1016/j.ajog.2010.11.013
- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2017. NCHS Data Brief, no 329. Hyattsville, MD: National Center for Health Statistics. 2018.
- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2018. NCHS Data Brief, no 356. Hyattsville, MD: National Center for Health Statistics. 2020.

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

122

122

REFERENCES: STIMULANT USE

- Disorder stimulant use management of - downloads.asam.org. (n.d.). https://downloads.asam.org/sitefinity-production-blobs/docs/default-source/quality-science/stud_guideline_document_final.pdf?sfvrsn=71094b38_1
- Kalaitzopoulos, D.-R., Chatzistergiou, K., Amyli, A.-L., Kokkinidis, D. G., & Goulis, D. G. (2018). Effect of Methamphetamine Hydrochloride on Pregnancy Outcome. *Journal of Addiction Medicine*, 12(3), 220–226. doi:10.1097/adm.0000000000000391
- Lee, N. K., Jenner, L., Harney, A., & Cameron, J. (2018). Pharmacotherapy for amphetamine dependence: A systematic review. *Drug and Alcohol Dependence*. doi:10.1016/j.drugalcdep.2018.06.038
- Mayo Clinic Laboratories. (2020). Amphetamine-Type Stimulants (ATS). <https://www.mayocliniclabs.com/test-info/drug-book/amphetamine.html>
- NCHS, National Vital Statistics System. Estimates for 2019 and 2020 are based on provisional data. Estimates for 2015–2018 are based on final data (available from: https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm)
- NIDA. 2020, April 3. California: Opioid-Involved Deaths and Related Harms. Retrieved from <https://www.drugabuse.gov/drug-topics/opioids/opioid-summaries-by-state/california-opioid-involved-deaths-related-harms> on 2020, October 7
- NIHCM Foundation. (2020). Beyond Opioids: Rapid Increase in Drug Deaths Involving Stimulants. <https://www.nihcm.org/categories/beyond-opioids-rapid-increase-in-drug-deaths-involving-stimulants>
- Oliva, EM, Bowe, T., Harris, A. H., & Trafton, J. A. (2013). Datapoints: False starts in psychotherapy for substance use disorders and PTSD in the VHA. *Psychiatric Services*, 64(8), 722.
- Paulus, M (2020) Neurobiology, clinical presentation, and treatment of methamphetamine use disorder a review. *JAMA Psychiatry* 77(9): 959-66.

© 2025 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

123

123

REFERENCES: STIMULANT USE

- Peirce, JM, et al. (2006). Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: A National Drug Abuse Treatment Clinical Trials Network study. *Archives of General Psychiatry*, 63(2), 201–208. <https://doi.org/10.1001/archpsyc.63.2.201>
- Petry N., T. J. (2004). Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom? *Addiction*, 349–360.
- Sever, P. S., Dring, L. G., & Williams, R. T. (1975). The metabolism of (?)-ephedrine in man. *European Journal of Clinical Pharmacology*, 9(2-3), 193–198. doi:10.1007/bf00614017
- Smid, M. C., Metz, T. D., & Gordon, A. J. (2019). Stimulant Use in Pregnancy: An Under-recognized Epidemic Among Pregnant Women. *Clinical obstetrics and gynecology*, 62(1), 168–184. <https://doi.org/10.1097/GRF.0000000000000418>
- Substance Abuse and Mental Health Services Administration (SAMHSA). Treatment of Stimulant Use Disorders. SAMHSA Publication No. PEP20-06-01-001 Rockville, MD: National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration, 2020. <https://store.samhsa.gov/product/Treatment-of-Stimulant-Use-Disorder/PEP20-06-01-001>
- Substance Abuse and Mental Health Services Administration. (2017). Medical Review Officer Guidance Manual for Federal Workplace Drug Testing Programs. https://www.samhsa.gov/sites/default/files/workplace/mro-guidance-manual-oct2017_2.pdf
- Substance Abuse and Mental Health Services Administration. (2025). Using SAMHSA funds to implement evidence-based contingency management services. SAMHSA Publications and Digital Products. <https://library.samhsa.gov/product/using-samhsa-funds-implement-evidence-based-contingency-management-services/pep24-06-001>
- U.S. Drug Enforcement Administration, Diversion Control Division. (2019). NFLIS-Drug Special Report: Methamphetamine Reported in NFLIS, 2001–2017. Springfield, VA: U.S. Drug Enforcement Administration. <https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/12568NFLISDrugMethamphetamine.pdf>
- Volkow, N. D., & Morales, M. (2015). The Brain on Drugs: From Reward to Addiction. *Cell*, 162(4), 712–725. doi:10.1016/j.cell.2015.07.046
- Werner, D. D. and DePhillips, D. (2020, August 12). Contingency Management for People Experiencing Homelessness - Homeless and Housing Resource Network SAMHSA Webinar. Washington DC, Washington DC.

© 2025 Health Management Associates, Inc. All Rights Reserved.


HEALTH MANAGEMENT ASSOCIATES

124

124



125



126

CHEMSEX

Definition:
 Chemsex (also known as sexualized drug use – SDU) is the **use of drugs to enhance sexual experience**. Common drugs used include methamphetamine, gamma-hydroxybutyrate (GHB), gamma-butyrolactone (GBL), cocaine, ketamine, poppers (amyl nitrite) or cannabis (the latter two gave rise to the term SDU).

What You Should Know:

- Chemsex is popular among some gay, bisexual, transgender, and queer persons, **but can be experienced by persons of any gender**
- Chemsex participants have higher odds of condomless anal sex with partners of different or unknown HIV status (bareback sex)
- Persons engaged in Chemsex have greater risk of acquiring sexually transmitted infections (STIs) and hepatitis C (HCV)
- Participants are at higher risk of HIV transmission
- The association with sexual risk indicates the importance of promoting harm reduction among this population (e.g., condoms, PrEP, PEP, drug knowledge).





© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 127




127

CHEMSEX

Common Terminology Used to Communicate the Desire to Engage in Chemsex

Injecting	Meth	GHB	Ketamine	ChemSex
Pointing, slamming, darts	Blowing clouds, Cloudy, ice cream, tea, T, tina	Water, Gina, Swirling	K, Special K	Party, PNP, Party and play

© 2020 Health Management Associates, Inc. All Rights Reserved. HEALTH MANAGEMENT ASSOCIATES 128

128

IMPACT OF CHEMSEX DRUGS

- » Engaging in chemsex can be managed by some. This can mean that there is minimal impact on an individual's general wellbeing, work, relationships with partners, friends, and family.
- » For others it can prove problematic, and individuals may experience:
 - impaired decision making
 - it dominates social life and free time
 - can lead to chaotic sexual encounters
 - sexual boundaries are often crossed while high
 - issues around sexual consent
 - impact on sexual health: Hep C, HIV, as well as other STI's
 - behaviors associated with addiction
 - impact on mental health
 - health issues associated with injecting drugs
 - being vulnerable to mental and physical harm by others
 - isolation
 - unmanageable comedowns
 - suicidal ideation
 - an impact on work performance
 - a breakdown of personal relationships

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

129

129

METHAMPHETAMINE AND ITS IMPACT ON HIV INFECTION

Methamphetamine use:

- » Increases sexual desire, impairs judgment, and provides energy and confidence to engage in sexual activity for long periods of time (hyper-sexual)
- » Causes erectile dysfunction
- » Causes mucosal dryness
- » Decreases adherence to HIV treatment and medical follow-up
- » Increases HIV replication
- » Accelerates progress of HIV-related dementia

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

130

130

DOES METHAMPHETAMINE ACCELERATE HIV AND HCV?

- » In test tube studies, when methamphetamine is added to immune cells, it significantly increases HIV replication
 - » Particularly in CD4 cells and monocytes (white blood cells)
- » In mouse models, methamphetamine activated a portion of the HIV genetic code (long terminal repeat – LTR), prompting cells to release a protein tied to more rapid HIV disease progression
- » The Journal of Viral Hepatitis published a study indicating that methamphetamine increases Hepatitis C replication.

Source: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675873/>

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

131

131

HIV AND HEPATITIS C


132

132

HIV AND HEPATITIS C CO-INFECTIONS

Hepatitis C and HIV
are often-overlooked consequences of America's **opioid crisis**.

EIGHT IN TEN
new Hepatitis C infections in the U.S. are transmitted through **injection drug use**.



Nearly **ONE IN TEN**
new HIV infections in 2015 were due to **injection drug use**.

HepVu.org SOURCE: U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION HepVu

HEALTH MANAGEMENT ASSOCIATES 133

133

HIV AND HEPATITIS C CO-INFECTIONS


- » In 2023 in Minnesota, there were 31,942 chronic cases of HCV
- » 8,140 Co-infected for HIV and HCV
- » The U.S. Public Health Service/Infectious Diseases Society of America guidelines recommend that all HIV-infected persons be screened for HCV infection (CDC, 2014).

HepVu.org SOURCE: Minnesota Department of Health, 2023; CDC, 2014; IDSA, 2015

HEALTH MANAGEMENT ASSOCIATES 134

134

HIV AND HEPATITIS C CO-INFECTIONS



Nine states represent more than half, or **52%** of all people living with **Hepatitis C** nationwide.

Estimated Number of People Living with Hepatitis C, 2013-2016

0 - 10,000	10,001 - 25,000	25,001 - 50,000	50,001 - 75,000	75,000+
------------	-----------------	-----------------	-----------------	---------

HepVu.org SOURCE: HepVu

HEALTH MANAGEMENT ASSOCIATES 135

135

QUESTIONS?

HEALTH MANAGEMENT ASSOCIATES 136

136

NEXT STEPS

- » Join us next week for Session 4!
- » Your registration should have included a reoccurring calendar invite for all four sessions
- » Please complete the evaluation for this session that will be sent out after via email (evaluations must be completed for those seeking CEU/CME credits).

Follow-up questions?
Contact Gabriel Velazquez at
gvelazquez@healthmanagement.com

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

137

137

AGENDA FOR WEBINAR SERIES

Session	Topics
#1 WEDNESDAY, JANUARY 9 12:00 pm to 3:00 pm	<input type="checkbox"/> Screening, and Assessment <input type="checkbox"/> Understanding HIV <input type="checkbox"/> HIV Testing, Treatment and Prevention <input type="checkbox"/> The Science of Addiction
#2 WEDNESDAY, JANUARY 15 12:00 pm to 3:00 pm	<input type="checkbox"/> Ethical and Legal Issues <input type="checkbox"/> Funding and Policy Considerations <input type="checkbox"/> HIV Risk Reduction <input type="checkbox"/> SUD Harm Reduction <input type="checkbox"/> HIV and Stigma <input type="checkbox"/> Motivational Interviewing
#3 WEDNESDAY, JANUARY 22 12:00 pm to 3:00 pm	<input type="checkbox"/> Working with Justice Involved Persons <input type="checkbox"/> Substance Use Disorder Treatment with Medications <input type="checkbox"/> Mental Health Treatment and Counseling <input type="checkbox"/> Stimulant Use <input type="checkbox"/> Chem Sex
#4 WEDNESDAY, JANUARY 29 12:00 pm to 3:00 pm	<input type="checkbox"/> Cultural, Racial and Sexual Identities <input type="checkbox"/> Pregnancy and HIV, SUD/ODU <input type="checkbox"/> Accessing, Obtaining, and Integrating Services for Individuals with HIV and SUD in Minnesota

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

138

138

GLOSSARY OF TERMS (REVISITED)

- » Sexual orientation – a person’s identity in relation to the gender or genders to which they are sexually attracted (straight, gay, lesbian, asexual, bisexual, pansexual)
- » Gender identity and/or expression - internal perception of one’s gender; how one identifies or expresses oneself.
 - » Cisgender – a term used to describe a person whose gender identity aligns with those typically associated with the sex assigned to them at birth
 - » Transgender – refers to an individual whose current gender identity and/or expression differs from the sex they were assigned at birth (may have transitioned or be transitioning in how they are living)
 - » Gender Expansive - refers to an individual who expresses identity along the gender spectrum (genderqueer, gender nonconforming, nonbinary, agender, two spirit)
- » Sexual Minority – refers to a group whose sexual identity orientation or practices differ from the majority of and are marginalized by the surrounding society.

SOURCE: Centers for Educational Justice and Community Engagement, UC Berkeley

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

139

139

GLOSSARY OF TERMS (REVISITED)

- » Race - is usually associated with inherited physical, social and biological characteristics. In this context that means race is associated with biology. Institutionalized in a way that has profound consequences (White, African American, American Indian Alaskan Native, Native Hawaiian or Pacific Islander)”
- » Ethnicity - a term used to categorize a group of people with whom you share learned characteristics and identify according to common racial, national tribal, religious, linguistic, or cultural origin or background. (Hispanic, Non-Hispanic Black, Non-Hispanic Black, etc.)

SOURCE: US Office of Management and Budget: Federal Register Vol. 62(210): 58782

© 2020 Health Management Associates, Inc. All Rights Reserved.

HEALTH MANAGEMENT ASSOCIATES

140

140

COMMON ACRONYMS (REVISITED)

ART – Antiretroviral therapy
AUD – Alcohol use disorder
IDU – Injection or intravenous drug use
MSM – Men who have sex with men
OUD – Opioid use disorder
PEH – Person(s) experiencing homelessness

PEP – Post-exposure prophylaxis
PrEP – Pre-exposure prophylaxis
PLWH – Person(s) living with HIV
PWID – Person(s) who injects drugs
SUD – Substance use disorder